Cromolyn Sodium Inhalation Solution, USP Rx only

Manufacturer
Teva Pharmaceuticals USA, Inc.
Effective date
2023-12-14
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
9
Source
full-release
Hydrated at
2026-05-31 20:59:10

Key Label Information#

Uses

INDICATIONS AND USAGE

Cromolyn sodium inhalation solution USP is a prophylactic agent indicated in the management of patients with bronchial asthma. In patients whose symptoms are sufficiently frequent to require a continuous program of medication, cromolyn sodium inhalation solution USP is given by inhalation on a regular daily basis (see DOSAGE AND ADMINISTRATION ). The effect of cromolyn sodium is usually evident after several weeks of treatment, although some patients show an almost immediate response. In patients who develop acute bronchoconstriction in response to exposure to exercise, toluene diisocyanate, environmental pollutants, etc., cromolyn sodium should be given shortly before exposure to the precipitating factor (see DOSAGE AND ADMINISTRATION ).

CONTRAINDICATIONS

Cromolyn sodium inhalation solution is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium.

Warnings

CONTRAINDICATIONS

Cromolyn sodium inhalation solution is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium.

WARNINGS

Cromolyn sodium inhalation solution has no role in the treatment of status asthmaticus. Anaphylactic reactions with cromolyn sodium administration have been reported rarely.

Directions And Dosage

OVERDOSAGE

There is no clinical syndrome associated with an overdosage of cromolyn sodium. Acute toxicity testing in a wide variety of species has demonstrated that toxicity with cromolyn sodium occurs only with very high exposure levels, regardless of whether administration was parenteral, oral or by inhalation. Parenteral administration in mice, rats, guinea pigs, hamsters, and rabbits demonstrated a median lethal dose of approximately 4000 mg/kg. Intravenous administration in monkeys also indicated a similar pattern of toxicity. The highest dose administered by the oral route in rats and mice was 8000 mg/kg, (approximately 261 and 130 times, respectively, the maximum recommended human daily inhalation dose on a mg/m 2 basis) and at this dose level no deaths occurred. By inhalation, even in long term studies, it proved impossible to achieve toxic dose levels of cromolyn sodium in a range of mammalian species.

DOSAGE AND ADMINISTRATION

For management of bronchial asthma in adults and pediatric patients (two years of age and over), the usual starting dosage is the contents of one vial administered by nebulization four times a day at regular intervals. Drug stability and safety of cromolyn sodium inhalation solution when mixed with other drugs in a nebulizer have not been established. Patients with chronic asthma should be advised that the effect of cromolyn sodium inhalation solution therapy is dependent upon its administration at regular intervals, as directed. Cromolyn sodium inhalation solution should be introduced into the patient's therapeutic regimen when the acute episode has been controlled, the airway has been cleared and the patient is able to inhale adequately. For the prevention of acute bronchospasm which follows exercise or exposure to cold dry air, environmental agents (e.g., animal danders, toluene diisocyanate, pollutants), etc., the usual dose is the contents of one vial administered by nebulization shortly before exposure to the precipitating factor. It should be emphasized to the patient that the drug is poorly absorbed when swallowed and is not effective by this route of administration. For additional information, see the accompanying leaflet entitled “Living a Full Life with Asthma” .

Other Label Information

Package/Label Display Panel

NDC 0172-6406-49 Cromolyn Sodium Inhalation Solution, USP 20 mg/2 mL Steri-Neb™ brand of Sterile Unit-Dose Vials For Oral Inhalation Use Only Not for Injection Aqueous Solution for Nebulization PRESERVATIVE FREE Rx only 12 pouches of five 2 mL vials each (60 unit-dose vials)

Label Images#

image-1
image-1
image-2
image-2
image-3
image-3
image-4
image-4
image-5
image-5
image-6
image-6
image-7
image-7
image-8
image-8
image-9
image-9
image-10
image-10

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
831246cromolyn sodium 20 MG in 2 ML Inhalation SolutionPSN9
831246cromolyn sodium 10 MG/ML Inhalation SolutionSCD9
831246cromolyn sodium 20 MG per 2 ML Inhalation SolutionSY9

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CROMOLYN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d745b171-bd61-e8c6-cc94-d4add278788bProduct name320230113
a7fea5a7-679e-334b-faff-75e43fb3beb5Product name220171208

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0172-6406-05Cromolyn Sodium2 mL in 1 VIAL, SINGLE-DOSESOLUTION29
0172-6406-05Cromolyn Sodium5 in 1 POUCHSOLUTION59
0172-6406-49Cromolyn Sodium12 in 1 CARTONSOLUTION129

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0172-6406CROMOLYN SODIUM SOLUTION [TEVA PHARMACEUTICALS USA, INC.]9Current NDC, Legacy NDC, 3 package rows20240201_8fe37a7a-edd6-4733-bb7e-e01c1906aeba.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0172-6406-05ML - Milliliter0172-64066bc54976-9530-45b5-bc30-cf12377e21b012015-05-05
0172-6406-49ML - Milliliter0172-64068ea1bd01-526a-4f58-a460-0ed81f61952d12012-07-24
0172-6406-59ML - Milliliter0172-6406ca7a2596-94b6-4733-872e-5f49965417b512012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
CROMOLYN SODIUMACTIVE INGREDIENTQ2WXR1I0PK3
CROMOLYNACTIVE MOIETYY0TK0FS77W3
WATERINACTIVE INGREDIENT059QF0KO0R3

Products#

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0172-64060172-6406-05, 0172-6406-49

Ingredients#

Name, UNII, Kind table
NameUNIIKind
CROMOLYN SODIUMQ2WXR1I0PKACTIB
WATER059QF0KO0RIACT

Complete SPL Sections#

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

For Oral Inhalation Use Only - Not for Injection

DESCRIPTION

DESCRIPTION SECTION

The active ingredient of cromolyn sodium inhalation solution, USP is cromolyn sodium, USP. It is an inhaled anti-inflammatory agent for the preventive management of asthma. Cromolyn sodium, USP is chemically designated as disodium 5,5'- [(2-hydroxytrimethylene)dioxy] bis [4-oxo-4 H -1-benzopyran-2-carboxylate]. The molecular formula is C 23 H 14 Na 2 O 11 ; the molecular weight is 512.34. Cromolyn sodium, USP is a water-soluble, odorless, white, hydrated crystalline powder. It is tasteless at first, but leaves a slightly bitter aftertaste. Cromolyn sodium inhalation solution USP is clear, colorless to pale yellow, sterile and has a target pH of 5.5. The structural formula is: Each 2 mL vial for oral inhalation use only contains 20 mg cromolyn sodium, USP in water for injection, USP.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

In vitro and in vivo animal studies have shown that cromolyn sodium inhibits sensitized mast cell degranulation which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of mediators from mast cells. Studies show that cromolyn sodium indirectly blocks calcium ions from entering the mast cell, thereby preventing mediator release. Cromolyn sodium inhibits both the immediate and non-immediate bronchoconstrictive reactions to inhaled antigen. Cromolyn sodium also attenuates bronchospasm caused by exercise, toluene diisocyanate, aspirin, cold air, sulfur dioxide, and environmental pollutants. Cromolyn sodium has no intrinsic bronchodilator or antihistamine activity. After administration by inhalation, approximately 8% of the total cromolyn sodium dose administered is absorbed and rapidly excreted unchanged, approximately equally divided between urine and bile. The remainder of the dose is either exhaled or deposited in the oropharynx, swallowed and excreted via the alimentary tract.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Cromolyn sodium inhalation solution USP is a prophylactic agent indicated in the management of patients with bronchial asthma. In patients whose symptoms are sufficiently frequent to require a continuous program of medication, cromolyn sodium inhalation solution USP is given by inhalation on a regular daily basis (see DOSAGE AND ADMINISTRATION ). The effect of cromolyn sodium is usually evident after several weeks of treatment, although some patients show an almost immediate response. In patients who develop acute bronchoconstriction in response to exposure to exercise, toluene diisocyanate, environmental pollutants, etc., cromolyn sodium should be given shortly before exposure to the precipitating factor (see DOSAGE AND ADMINISTRATION ).

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Cromolyn sodium inhalation solution is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium.

WARNINGS

WARNINGS SECTION

Cromolyn sodium inhalation solution has no role in the treatment of status asthmaticus. Anaphylactic reactions with cromolyn sodium administration have been reported rarely.

PRECAUTIONS

PRECAUTIONS SECTION

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Clinical experience with the use of cromolyn sodium suggests that adverse reactions are rare events. The following adverse reactions have been associated with cromolyn sodium: cough, nasal congestion, nausea, sneezing, and wheezing. Other reactions have been reported in clinical trials; however, a causal relationship could not be established: drowsiness, nasal itching, nose bleed, nose burning, serum sickness, and stomachache. In addition, adverse reactions have been reported with cromolyn sodium for inhalation capsules. The most common side effects are associated with inhalation of the powder and include transient cough (1 in 5 patients) and mild wheezing (1 in 25 patients). These effects rarely require treatment or discontinuation of the drug. Information on the incidence of adverse reactions to cromolyn sodium for inhalation capsules has been derived from U.S. postmarketing surveillance experience. The following adverse reactions attributed to cromolyn sodium, based upon recurrence following readministration, have been reported in less than 1 in 10,000 patients: laryngeal edema, swollen parotid gland, angioedema, bronchospasm, joint swelling and pain, dizziness, dysuria and urinary frequency, nausea, cough, wheezing, headache, nasal congestion, rash, urticaria and lacrimation. Other adverse reactions have been reported in less than 1 in 100,000 patients, and it is unclear whether these are attributable to the drug: anaphylaxis, nephrosis, periarteritic vasculitis, pericarditis, peripheral neuritis, pulmonary infiltrates with eosinophilia, polymyositis, exfoliative dermatitis, hemoptysis, anemia, myalgia, hoarseness, photodermatitis, and vertigo.

OVERDOSAGE

OVERDOSAGE SECTION

There is no clinical syndrome associated with an overdosage of cromolyn sodium. Acute toxicity testing in a wide variety of species has demonstrated that toxicity with cromolyn sodium occurs only with very high exposure levels, regardless of whether administration was parenteral, oral or by inhalation. Parenteral administration in mice, rats, guinea pigs, hamsters, and rabbits demonstrated a median lethal dose of approximately 4000 mg/kg. Intravenous administration in monkeys also indicated a similar pattern of toxicity. The highest dose administered by the oral route in rats and mice was 8000 mg/kg, (approximately 261 and 130 times, respectively, the maximum recommended human daily inhalation dose on a mg/m 2 basis) and at this dose level no deaths occurred. By inhalation, even in long term studies, it proved impossible to achieve toxic dose levels of cromolyn sodium in a range of mammalian species.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

For management of bronchial asthma in adults and pediatric patients (two years of age and over), the usual starting dosage is the contents of one vial administered by nebulization four times a day at regular intervals. Drug stability and safety of cromolyn sodium inhalation solution when mixed with other drugs in a nebulizer have not been established. Patients with chronic asthma should be advised that the effect of cromolyn sodium inhalation solution therapy is dependent upon its administration at regular intervals, as directed. Cromolyn sodium inhalation solution should be introduced into the patient's therapeutic regimen when the acute episode has been controlled, the airway has been cleared and the patient is able to inhale adequately. For the prevention of acute bronchospasm which follows exercise or exposure to cold dry air, environmental agents (e.g., animal danders, toluene diisocyanate, pollutants), etc., the usual dose is the contents of one vial administered by nebulization shortly before exposure to the precipitating factor. It should be emphasized to the patient that the drug is poorly absorbed when swallowed and is not effective by this route of administration. For additional information, see the accompanying leaflet entitled “Living a Full Life with Asthma” .

HOW SUPPLIED

HOW SUPPLIED SECTION

Cromolyn sodium inhalation solution, USP Unit-Dose 2 mL Vial is supplied as a colorless to pale yellow solution containing 20 mg cromolyn sodium, USP, in water for injection, USP, with 5 vials per foil pouch in a carton as listed below. 60 vials per carton (NDC 0172-6406-49). Each vial is made from a low density polyethylene (LDPE) resin. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Do not use if solution is discolored or contains a precipitate. Retain in foil pouch until time of use. PROTECT FROM LIGHT. Keep this and all medications out of the reach of children. Manufactured In England By: Norton Healthcare Limited Runcorn, Cheshire WA7 3FA UK Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. B 12/2023

LIVING A FULL LIFE WITH ASTHMA

SPL PATIENT PACKAGE INSERT SECTION

PATIENT INSTRUCTIONS Cromolyn Sodium Inhalation Solution, USP You or your child may be among the millions of Americans who have asthma. For most patients, asthma need not limit your lifestyle, if you closely follow the asthma management plan your doctor provides you. Your doctor has given you this instruction sheet to help you learn more about asthma and ways to control it. WHAT IS ASTHMA? Asthma is a disease that causes patients to have difficulty breathing. Asthma “attacks” occur when the air passages (airways) to the lungs close up, blocking air from passing through. The closing up is caused by two things: The muscles around the airways tighten (constrict) making the airway narrower, and The passage lining swells and produces larger amounts of mucus (a sticky liquid normally found in airways). This swelling is caused by a certain type of inflammation that can build up in the airways of patients with asthma. Inflammation and the airway sensitivity that results from it cause further attacks to occur. WHAT CAUSES THESE ATTACKS? Asthma experts know that patients with asthma have attacks because their airways are inflamed and over reactive. Their lungs become super-sensitive to certain irritants or “triggers”, such as cold dry air, pollen, smoke, or cat dander. In the presence of such triggers, someone with asthma may have an attack, and attacks may occur more often. Asthma triggers fall into 6 categories: Substances that cause allergies (pollens, animal dander, molds, house dust, some foods and medicines) Infections that affect breathing (colds, flu) Emotional stress (difficult situations at home, school, or work) Strenuous exercise Irritating gases (chlorine, perfume, tobacco smoke) Sudden changes in temperature or humidity HOW TO PREVENT ASTHMA ATTACKS No medicine or procedure will “cure” asthma. The key to asthma relief, therefore, is to prevent attacks and to relieve attack symptoms if they do occur. A successful prevention plan* will do the following: Keep your activities, including exercise, at normal levels. Keep your lungs functioning normally or at a near-normal level. Prevent symptoms such as coughing or breathlessness that can keep you up at night, or occur in the early morning hours, or after exertion. Prevent asthma attacks from happening. Avoid unpleasant or harmful side effects that may result from using asthma medicine. The best way to prevent asthma attacks is to avoid the triggers that bother you or your child. Try to identify the specific things that cause problems for you - things such as certain foods, house dust, or animal dander. Avoiding these triggers may be difficult or unpleasant. You may need to find a new home for a family pet or remove a carpet or a favorite stuffed toy. Even though these steps are difficult, they may be necessary in order to help prevent asthma attacks. If house dust is a trigger, remove dust-collectors such as feather pillows, mattresses, quilts, and carpets from the bedroom. Mattresses and pillows can be covered with allergen-free covers. If a certain food triggers attacks, keep it out of your diet. Irritants in the air can be reduced by air conditioning, electrostatic air filters, or small-pore (HEPA) filters. Be careful of certain medicines. Aspirin and aspirin-like pain relievers, for example, can trigger attacks in some people and should be avoided if they do. * Adapted from the National Heart, Lung, and Blood Institute: Guidelines for the Diagnosis and Management of Asthma. National Asthma Education Program, Expert Panel Report, 1991. OTHER DO’S AND DON’TS Anyone with asthma should stick to a healthy, balanced diet, get lots of rest and moderate exercise, and follow these do’s and don’ts: Don’t smoke, and don’t stay in the same room with people that do. Avoid fresh paint. Avoid sudden changes of temperature. Don’t go in and out of extremely cool air-conditioned buildings during hot weather. Stay home in extremely cold weather, if possible. Stay away from people with cold or flu. Try to avoid emotionally upsetting situations. Drink lots of liquids. Don’t overdo, but follow a regular exercise plan, including activities that help develop lung capacity. Don’t take any medicine on your own without asking your doctor first. Take all medicines your doctor prescribes, as much and as often as you are told. Avoid taking sleeping pills or sedatives, even if asthma keeps you awake. Prop yourself up with extra pillows until your asthma medicine takes effect. Avoid breathing in insecticides, deodorants, cleaning fluids, chlorine, or other irritating gases. ASTHMA MEDICINES Preventive Medicine Your doctor knows that, besides relieving an attack when it happens, it is also important to prevent attacks from occurring in the first place. Therefore, he or she has prescribed for you cromolyn sodium, a medicine that prevents asthma attacks by making airways less sensitive to asthma triggers. It works by stabilizing cells in the airway lining called mast cells. During an asthma attack, these cells become unstable and give off chemicals called mediators that cause inflammation and asthma attacks. By preventing mediator release, cromolyn sodium works to prevent asthma attacks. Bronchodilators When someone is having an asthma attack, he or she needs a medicine called a bronchodilator to open up (dilate) the blocked airways in order to relieve asthma attacks. Your doctor may have already prescribed this medicine for you to use at that time. HOW WILL CROMOLYN SODIUM WORK FOR YOU? To get the best possible results, follow your doctor’s instructions carefully when you first take cromolyn sodium. Your doctor may tell you to take cromolyn sodium 10 to 15 minutes before you exercise or come into contact with a specific trigger, such as a cat. Usually, however, you will be told to take cromolyn sodium on a regular basis, probably starting at four times a day. It is crucial that you take cromolyn sodium, regularly , as often as your doctor recommends, even though you have no asthma symptoms at the time. Cromolyn sodium starts working right away but when you first begin taking it, you may have a lot of inflammation in your airways. Therefore, it may take up to two weeks (or perhaps one month) of regular treatment to bring your asthma under control. Do not stop taking cromolyn sodium or skip any doses without first talking with your doctor. When you start using cromolyn sodium for the first time, your doctor may ask you to keep a diary showing when you have any symptoms, if and when you have trouble sleeping, how often you wheeze or cough, and other notes to help determine how effective cromolyn sodium will be to help you prevent asthma attacks. Your doctor may also recommend the use of a peak flow meter daily to help you better assess your progress. While taking cromolyn sodium on a regular basis, you may need to take a bronchodilator-type medicine to treat occasional symptoms or attacks. While taking cromolyn sodium, you should continue taking your other medications until your doctor advises you otherwise. HOW TO TAKE CROMOLYN SODIUM Be sure to follow instructions carefully when you are shown how to take cromolyn sodium inhalation solution. CARE AND STORAGE Cromolyn sodium nebulizer solution should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Retain in foil pouch until time of use. PROTECT FROM LIGHT. Do not use if it contains a precipitate (particles or cloudiness) or becomes discolored. Keep this and all medications out of the reach of children. NOTE: In case of difficulty consult your doctor or pharmacist Manufactured In England By: Norton Healthcare Limited Runcorn, Cheshire WA7 3FA UK Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. B 12/2023 INSTRUCTIONS FOR USE Cromolyn Sodium Inhalation Solution, USP An aqueous solution for nebulization NOT FOR INJECTION For best results, follow these instructions exactly and observe Care and Storage directions. METHOD OF ADMINISTRATION ...

Package/Label Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0172-6406-49 Cromolyn Sodium Inhalation Solution, USP 20 mg/2 mL Steri-Neb™ brand of Sterile Unit-Dose Vials For Oral Inhalation Use Only Not for Injection Aqueous Solution for Nebulization PRESERVATIVE FREE Rx only 12 pouches of five 2 mL vials each (60 unit-dose vials)

Source Document#

Source XML